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A B S T R A C T
The causes of genetic epilepsies are unknown in the majority of patients. HCN ion channels have a widespread
expression in neurons and increasing evidence demonstrates their functional involvement in human epilepsies.
Among the four known isoforms, HCN1 is the most expressed in the neocortex and hippocampus and de novo
HCN1 point mutations have been recently associated with early infantile epileptic encephalopathy. So far, HCN1
mutations have not been reported in patients with idiopathic epilepsy. Using a Next Generation Sequencing
approach, we identiﬁed the de novo heterozygous p.Leu157Val (c.469C > G) novel mutation in HCN1 in an
adult male patient aﬀected by genetic generalized epilepsy (GGE), with normal cognitive development.
Electrophysiological analysis in heterologous expression model (CHO cells) and in neurons revealed that L157V
is a loss-of-function, dominant negative mutation causing reduced HCN1 contribution to net inward current and
responsible for an increased neuronal ﬁring rate and excitability, potentially predisposing to epilepsy. These data
represent the ﬁrst evidence that autosomal dominant missense mutations of HCN1 can also be involved in GGE,
without the characteristics of epileptic encephalopathy reported previously. It will be important to include HCN1
screening in patients with GGE, in order to extend the knowledge of the genetic causes of idiopathic epilepsies,
thus paving the way for the identiﬁcation of innovative therapeutic strategies.
1. Introduction
Although the genetic causes of epilepsy remain unknown in most
patients, signiﬁcant progress in the understanding of the pathogenic
mechanisms underlying the disease has been recently achieved, based
on the advancement of speciﬁc diagnostic tools. Thanks to the devel-
opment of the Next Generation Sequencing (NGS) techniques, the
number of genes recognized to contribute, when defective as a
consequence of a mutation, to diﬀerent forms of epilepsy has grown
substantially. This has allowed to clarify the basis of some of the spe-
ciﬁc mechanisms leading to the epileptic phenotype and, more im-
portantly, has laid the basis for the development of innovative ther-
apeutic approaches based on the mutations identiﬁed (Thomas and
Berkovic, 2014).
Recently, the genetic causes of epilepsies with infantile/childhood-
onset associated with developmental delay, such as the epileptic
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encephalopathies, have been identiﬁed in an increasing number of
cases. Speciﬁc ion channel mutations, modifying the channel properties
and aﬀecting neuronal discharge in a way that may help development
of epilepsy, have been identiﬁed in these patients (Thomas and
Berkovic, 2014).
Conversely, in the case of epilepsy without cognitive impairment,
such as genetic generalized epilepsy (GGE), the genetic basis is still
unresolved, although many cases have a clear familial transmission,
often with autosomal dominant inheritance. Studies of large cohorts of
patients, with both sporadic and familial cases, have shown that a
clearly identiﬁable genetic etiology of the disease is lacking in most
cases (Heinzen et al., 2012). The generally accepted view is that idio-
pathic epilepsies are likely determined by a complex interaction be-
tween genetic and environmental factors predisposing patients to the
development of a speciﬁc phenotype (Heinzen et al., 2012; Leu et al.,
2012). However, the complex dynamics regulating these mechanisms
are far from being clariﬁed.
Along with the ion channels already known to play a role in epi-
lepsy, a novel group of proteins recently proposed to play a role in the
pathogenesis of epilepsy is the family of the Hyperpolarization-acti-
vated Cyclic-Nucleotide-gated (HCN) channels. The four isoforms
(HCN1–4) of this family are the molecular correlates of native hy-
perpolarization-activated f channels carrying the “funny” current in
cardiomyocytes and the “h” current in neurons (If/Ih).
One of the most speciﬁc functions of HCN channels is their in-
volvement in generation and modulation of rhythmic activity, which is
typiﬁed by the role they play in the spontaneous activity and frequency
control of pacemaker cells of the heart (Brown et al., 1979;
DiFrancesco, 1993).
In the central nervous system (CNS), the HCN1, HCN2 and HCN4
isoforms are widely distributed and contribute to the generation of
neuronal activity, while the role of HCN3 is less well determined (Biel
et al., 2009).
Neuronal HCN channels are responsible for several important cel-
lular functions, including the contribution to cellular excitability and
plasticity phenomena in the brain.
The role of HCN channels in the control of neuronal excitability and
ﬁring has been demonstrated in several types of neurons (Robinson and
Siegelbaum, 2003; Biel et al., 2009), which directly implies a potential
involvement in pathological manifestations of neuronal activity such as
epilepsy (Baruscotti et al., 2010; Albertson et al., 2013; Benarroch,
2013; Shah et al., 2013).
Growing evidence for a relevant role of HCN channels in the pa-
thogenesis of epilepsy has in fact emerged in the last few years
(Difrancesco and Difrancesco, 2015; Oyrer et al., 2018). Data from
animal models show that the loss of HCN1 increases the dendritic input
resistance in cortical neurons, leading to greater synaptic integration
and ﬁring and thus predisposing to hyperexcitability, without however
generating spontaneous seizures (Huang et al., 2009; Santoro et al.,
2010). HCN2 knockout animal models exhibit spontaneous absence
seizures (Ludwig et al., 2003), and generalized epileptic activity has
been shown in a spontaneous mutation leading to truncation of the
HCN2 channel at the C terminus (Chung et al., 2009). Moreover,
pharmacological animal models of epilepsy show a remodeling of HCN
channels following the induction of status epilepticus, leading to an
enduring predisposition to spontaneous seizures (Jung et al., 2007;
Powell et al., 2008; Jung et al., 2011).
In patients, evidence is accumulating for HCN mutations associated
with epileptic phenotypes, although the data are still not suﬃcient to
draw a general paradigm linking HCN properties and epilepsy.
The ﬁrst study exploring the presence of HCN mutations in patients
with generalized epilepsy identiﬁed a single point mutation in the C-
linker region of HCN2, leading to a partial reduction of activity of the
mutant channel (Tang et al., 2008). Dibbens and colleagues later re-
ported a gain of function mutation of HCN2, due to a triple proline
deletion (delPPP), with higher prevalence in children aﬀected by either
febrile seizures (FS) or genetic epilepsy with febrile seizures plus (GEFS
+) than in controls (Dibbens et al., 2010). A study from our group led
to the identiﬁcation, in a patient with generalized epilepsy, of the ﬁrst
epilepsy-linked recessive mutation in HCN2 (E515K) causing an es-
sentially complete loss of channel function, with a signiﬁcant increase
in the activity of neuronal discharge and excitability (DiFrancesco et al.,
2011). In a later study the HCN2 p.S126L mutation was identiﬁed in
two subjects with FS (Nakamura et al., 2013). Functional character-
ization showed an increased Ih availability only at high temperatures
(38 °C), potentially contributing to hyperthermia-induced neuronal
hyperexcitability in these subjects (Nakamura et al., 2013). More re-
cently, de novo HCN1 mutations have been reported in early infantile
epileptic encephalopathy (EIEE) (Nava et al., 2014a), a severe condition
of infancy resembling the spectrum of Dravet syndrome and associated
in the majority of cases with mutations in SCN1A and PCDH19
(Depienne et al., 2009a; Depienne et al., 2009b). Some of the HCN1
mutations identiﬁed have been characterized in a CHO cell model, re-
sulting in a dominant gain-of-function eﬀect. Notably, HCN1 exon de-
letions have been reported in autism spectrum disorder without epi-
lepsy (Nava et al., 2014b). These results suggest that mutations altering
HCN1 channel function are poorly tolerated and can predispose to
neuronal hyperexcitability, but this may not be enough to cause seizure
development. So far, de novo HCN1 mutations have been associated
with severe EE of infancy, but there is still no clear-cut evidence for
their involvement in GGE (Tang et al., 2008; Dibbens et al., 2010;
DiFrancesco et al., 2011).
In this study, we report the identiﬁcation of a novel, de novo mu-
tation of HCN1 in one patient aﬀected by GGE. Functional analysis with
wild type and mutant channels transfected into CHO cells and neurons
show that this mutation determines a loss-of-function eﬀect and in-
creased neuronal excitability, potentially predisposing the proband to
the development of the disease.
2. Materials and methods
2.1. Patient recruitment
We recruited patients with the diagnosis of genetic generalized
epilepsy (GGE) and focal epilepsy of unknown origin according to de-
ﬁnition (Berg et al., 2010; Scheﬀer et al., 2017). For all patients in-
cluded, we collected information about gender, type of epilepsy (gen-
eralized, focal and combined generalized and focal) and inheritance of
the disease, considering it as either sporadic, when the patient is the
only aﬀected of the family, or familial, when at least one member of the
proband's family is aﬀected by epilepsy with similar features. In order
to identify a possible symptomatic etiology of seizures, clinical and
instrumental data of patients with epilepsy were carefully analyzed.
Structural causes of seizures, such as cerebrovascular disease, tumor or
trauma, were investigated with 1 or 1.5 T brain MRI with proper se-
quences (T1, T1 with Gadolinium, T2/FLAIR, Inversion Recovery).
Biochemical and hematological tests were performed to exclude meta-
bolic causes. Other seizure-provoking factors like antipsychotic or an-
tidepressant therapy, alcohol or drug dependency, infection of the
central nervous system were excluded. EEG was used to characterize
features of the disease. Subjects with symptomatic epilepsy were ex-
cluded from recruitment. A written informed consent was obtained
from all patients and/or from their parents for research purposes as
approved by the local Institutional Review Board of the Besta Institute
and S. Gerardo Hospital and by the Italian Ministry of Health. Upon
acceptance of the informed consent, patients underwent a small blood
withdrawal in EDTA anticoagulant for DNA extraction.
2.2. DNA extraction and genetic screening
Screening of HCN genes was performed on genomic DNA extracted
from whole blood using standard procedures (QIAamp DNA Blood Mini
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Kit; Qiagen), as previously reported (DiFrancesco et al., 2014;
DiFrancesco et al., 2015).
Mutations were identiﬁed by DNA sequencing (Bio-Fab Research).
Following the identiﬁcation of the novel p.Leu157Val mutation on
HCN1, the DNA of the proband and both sisters was analyzed with an
NGS gene panel. This analysis was conducted in order to rule out other
possible causative genetic factors associated with the patient's pheno-
type. We used a Nextera Rapid Capture method with Studio Design
software (Illumina, Inc., San Diego, CA, USA) for customizing a gene
panel for the analysis of the genes reported in Table 1. The mean of
coverage for this panel was 96%; the coverage of each gene is available
on request. The resulting sequences have been aligned to the reference
genome (GRCh37/hg19) using MiSeq software. Data analysis was ob-
tained using the following software: Illumina MiSeq Reporter vs 2.4.60,
Illumina Variant Studio vs 2.2, Qiagen CLC Genomics Workbench vs 7.0.
Variants with MAF > 1% reported in the dbSNP (https://www.ncbi.
nlm.nih.gov/projects/SNP/), 1000 Genome (browser.1000genomes.
org), EVS database (evs.gs.washington.edu) and ExAC database
(http://exac.broadinstitute.org/) were considered benign variants and
excluded from the report.
2.3. Construction of plasmids
The Wild Type (WT) HCN1 sequence was subcloned into the pIRES
vector. The point mutation 469C > G (L157 V) was introduced using
the QuikChange II XL site-directed mutagenesis kit (Thermoﬁscher)
with the following primers: forward (5′-gatttaataatgctta-
taatgatggttggaaatgtagtcatcataccagttg-3′), reverse (5′-caactggtatgatgac-
tacatttccaaccatcattataagcattattaaatc-3′).
2.4. Cell culture and transfection
Chinese Hamster Ovary (CHO) cells were maintained in F-12 Ham's
Medium (Euroclone) containing: 10% FBS (Gibco), 2% PenStrep
Solution (Sigma), 1 mM L-Glutamine (Sigma) and 1.5 g/L NaHCO3
(Sigma) at 37 °C in a 5% CO2 incubator. All animal procedures con-
formed to the Italian and UE laws (D. Lgs n° 2014/26, 2010/63/UE)
and approved by the University of Milano Ethical Committee and by the
Italian Minister of Health (protocol number 9/2013). Neonatal rat
cortical neurons were isolated from 3-day old rat pups (Envigo) as
previously reported (DiFrancesco et al., 2011). Brieﬂy, brains from rat
pups were isolated, placed into dishes containing ice-cold dissociation
medium (in mM: 134 Na-isethionic acid, 23 glucose, 15 HEPES, 2 KCl, 4
MgCl2, 0.1 CaCl2, and 10 kynurenic acid, pH 7.2). Cerebral cortex was
dissected, chopped into small pieces and digested in the dissociation
medium containing 1.3mg/mL protease (Sigma Aldrich) for 20min at
37 °C. After two washes with the dissociation medium, the mechanical
procedure was performed using a series of ﬁre-polished Pasteur pipettes
of decreasing size. 8× 105 neurons were plated onto poly-D-Lysine-
coated 35mm petri dishes containing Neuorbasal A culture medium
(Invitrogen) supplemented with 1mM Glutamax-1 (Invitrogen), B-27
(Life Technologies), 10 ng/mL β-FGF (Invitrogen), 50 U/mL penicillin G
(Sigma), and 50 μg/mL streptomycin (Sigma). After the isolation pro-
cedure, rat neonatal cortical neurons presented a limited dendritic ar-
borization and were mostly rounded up and expressed a negligible
endogenous Ih current, as previously shown (DiFrancesco et al., 2011).
The medium was replaced after 1 h in 5% CO2 and at 37 °C with Neu-
robasal A culture medium. Neurons were kept in 5% CO2 at 37 °C and
transfected the day after isolation. Transient transfections were per-
formed using the Lipofectamine 2000 kit (Life Technologies) for neu-
rons and Fugene HD (Promega) for CHO cells accordingly to manu-
facturer instructions. For neurons, 2.5 μL of Lipofectamine was used for
each 1 μg of cDNA. Lipofectamine 2000 was premixed with Serum Free
Optimem in a glass tube for 5min, and thereafter cDNA was added. The
mixture was kept 15min at room temperature, in the dark. The day
after the transfection, half of the media was changed. 36–48 h after
transfection, GFP-positive neurons were selected for patch-clamp ana-
lysis. For voltage-clamp experiments, 1.5 μg of either WT hHCN1- or
L157 V hHCN1-containing plasmids, or plasmids containing 0.75 μg of
both were transfected into either CHO cells or neurons. For current-
clamp experiments, neurons were transfected with either 0.5 μg of WT
hHCN1- or L157 V hHCN1-containing plasmids, or with plasmids con-
taining 0.25 μg of both.
2.5. Electrophysiology
Patch-clamp experiments in the whole-cell conﬁguration were car-
ried out 36–48 h after transfection on GFP-positive cells at room tem-
perature. CHO cells were initially superfused with the Tyrode solution
(mM: 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 5.5 D-glucose, 5 Hepes-
NaOH; pH 7.4). To dissect IHCN1, cells were superfused with a high
potassium solution containing (mM): 110 NaCl, 0.5 MgCl2, 1.8 CaCl2, 5
Hepes-NaOH, 30 KCl, 1 BaCl2, 2 MnCl2, pH 7.4. Patch-clamp pipettes
had a resistance of 5–7 MΩ when ﬁlled with the intracellular-like so-
lution containing (mM): 130 K-aspartate, 10 NaCl, 1 EGTA-KOH, 0.5
MgCl2, 2 ATP (Na-salt), 5 creatine phosphate, 0.1 GTP, 5 Hepes-KOH;
pH 7.2. Neurons were superfused with an external solution containing
(mM): 129 NaCl, 1.25 NaH2PO4, 1.8 MgSO4, 1.6 CaCl2, 3 KCl, 10 Na-
HEPES, 35 glucose, pH 7.4. The pipette solution was composed by
(mM): 120 K-gluconate, 15 KCl, 2 MgCl2, 0.2 EGTA, 20 phosphocrea-
tine, 2 ATP-disodium, 0.2 GTP-disodium, 0.1 leupeptin, 10 HEPES-
KOH, pH 7.2. IHCN1 activation curves were obtained with a standard
protocol consisting of test steps from a holding potential of−30mV to
the range− 35/−115mV, of a duration suﬃcient to reach steady-state
activation at each voltage, followed by a fully-activating step to
−125mV in CHO cells or− 115mV in neurons.
Activation curves were ﬁtted using the Boltzmann distribution:
y= 1/(1+ exp.((V-V1/2)/s)), where V is voltage, y the fractional acti-
vation, V1/2 the half-activation voltage, and s the inverse-slope factor.
IHCN1 activation time constants were obtained by ﬁtting the current
traces obtained from the activation protocol to a mono-exponential
function. Deactivation time constants were similarly obtained in CHO
cells by ﬁtting deactivating current traces recorded at voltages in the
range− 75/25mV after a fully activating step at −125mV.
Patch-clamp currents were acquired with a sampling rate of 2 KHz
and lowpass ﬁlter of 0.2 kHz. Currents were normalized to cell capa-
citance. Neither series resistance compensation nor leak correction
were applied. In current clamp experiments, neurons were held at
−70mV; the input resistance was measured in each cell prior to
starting clamp protocols and low input resistance cells (< 150 MΩ)
were discarded.
To investigate neuronal excitability, 2500ms depolarizing current
Table 1
List of genes analyzed in the customized panel.
DNA-Binding Protein ARX, CHD2, EMX2, FOXG1,HESX1, MBD5, MECP2, MEF2C, TCF4, ZEB2
Enzyme AFG3L2, ALDH7A1, CDKL5, CERS1, CSTB, CTSD, EMPM2A, GBA, KDM6A, KMT2D, MAGI2, NEU1, NHLRC1, PAFAHB1B, SMS, TPP1, EBE3A,
WWOX
Ion Channels and receptors ATP1A2, CACNA1A, CHRNA2, CHRNB2, CLCN2, GABRB3, GABRG2, GRIN2B, HCN1, HCN2, HCN4, KCNC1, KCNE2, KCNQ2, KCNQ3, KCNT1,
KCTD7, SCN1A, SCN1B, SCN2A, SCN8A
Structural Proteins ADGRG1, APBA2, CAV3, COL4A1, COL4A2, DCX, FLNA, GRASP, PCDH19, SLC2A1, SLC6A8, SLC9A6, TUBA1A, TUBB2B, TUBB3, TUBB8
Other ARHGEF9, C10ORF2, CLN6, DEPDC5, GOSR2, NPC1, NPC2, PEX5L, SCARB2, SRPX2, STX1B, SYNGAP1, TBC1D24, VLDLR
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steps were applied in current clamp mode in 10 pA increments from the
resting potential held at −70mV, and the ﬁring rate was measured
during the ﬁrst 500ms of current step. Spike threshold was deﬁned, for
each neuron, as the ﬁrst current step able to induce action potential
ﬁring.
Voltage “sags” were measured in response to 350 pA hyperpolar-
izing current steps of 800ms duration. We used the equation: Sag
ratio= (Vpeak-Vss)/Vpeak where Vpeak is the maximum voltage deﬂec-
tion and Vss is the steady-state voltage at the end of the hyperpolarizing
pulse (George et al., 2009). All protocols were designed using Pclamp
10.2 (Axon) and data were analyzed using Origin Pro 9 (Origin Lab).
2.6. Statistical analysis
Data were analyzed with Clampﬁt (Axon) and Origin Pro 9.
Activation curves were compared by analyzing the V1/2 using One-Way
ANOVA followed by Fisher's LSD post-hoc test; signiﬁcance level was
set to p= .05. Data outliers were excluded using Tukey's method. Data




We recruited 136 patients aﬀected by GGE (103), focal (31) and
combined generalized and focal epilepsies (2) for the genetic screening
of HCN channels. In one male patient, we identiﬁed the novel variant
p.Leu157Val (c.469C > G) on exon 2 of HCN1 in heterozygosis. The
extension of the analysis to the family of the proband (parents and
siblings) revealed that this was a de novo variant in the proband
(Fig. 1A). NGS analysis did not reveal other signiﬁcant epilepsy-related
genetic variants potentially linked to the phenotype of the proband.
Residue Leu157 of hHCN1 is localized about midway of the ﬁrst
transmembrane domain (S1) of the hHCN1 channel core (Fig. 1C) and is
conserved through all HCN isoforms (Fig. 1D).
3.2. Case description
The patient carrying the novel variant p.Leu157Val (c.469C > G)
on HCN1 was born from a physiological pregnancy, by non-con-
sanguineous parents. He presented a single febrile seizure at the age of
2 years. At the age of 19, he reported frequent episodes in cluster of
limbs myoclonus, especially at wakeup. He started treatment with low-
doses of valproate, with good control of the episodes. One year later,
the patient presented tonic-clonic generalized seizures with EEG
showing generalized sharp-waves, prevalent on the bilateral anterior
regions (Fig. 1B). Seizure control was obtained increasing the dose of
valproate treatment and this therapy has been continued until present.
Brain MRI was normal and a battery of cognitive tests showed a cog-
nitive level within normal limits.
The proband has a family history of epilepsy. The mother presented
a single febrile seizure in infancy, with no history of subsequent epi-
lepsy. Both sisters of the proband presented typical absence epilepsy in
infancy, with complete resolution in childhood. The clinical picture of
the proband is clearly distinct from that of his relatives.
3.3. Functional characterization of L157V HCN1 mutation in CHO cells
and cortical neurons
In order to assess the biophysical properties of L157V mutant
hHCN1 channels, we performed electrophysiological analysis of CHO
cells transfected with wild-type and/or mutant channels.
Typical traces of normalized IHCN1 currents recorded from cells
transfected with WT, L157V homomeric channels or heteromeric WT/
L157V channels are shown in Fig. 2A (left to right). Plotting mean
current-voltage relations in Fig. 2B shows that both L157V and WT/
L157V mutant channels carry about half of the current carried by WT
channels in the whole range of activation voltages, apparently ac-
cording to a dominant eﬀect of the mutation. Mean cell capacitance was
not diﬀerent among cells transfected with WT (42.1 ± 4.9 pF, n=14),
homozygous L157 V (37.0 ± 4.7 pF, n=17) or heterozygous WT/
L157 V channels (39.7 ± 5.2 pF, n=11) (p > .05).
L157V (n=28) and WT/L157 V (n=19) mutant channel also had
activation curves slightly, but signiﬁcantly, shifted to more positive
voltages (2.3 and 3.4mV, respectively, Fig. 2C), as well as slightly faster
activation and slower deactivation time constants (Fig. 2D) relative to
WT (n=25) channels.
To verify if the changes observed were also present in a neuronal
background, and to verify potential eﬀects on neuronal activity, we
expressed wild type and mutant channels in neonatal rat cortical neu-
rons (Fig. 3).
Representative normalized current traces recorded in neurons
transfected with WT, L157V or WT/L157V isoforms are shown in
Fig. 3A (top to bottom). Capacitances of neurons transfected with dif-
ferent constructs were similar. Mean values were (pF): WT 22.1 ± 2.1
(n=22), L157V 19.0 ± 2.1 (n=18), WT/L157V 19.2 ± 1.5
(n= 18) (p > .05).
As apparent from the mean current-voltage relations in Fig. 3B,
expression of mutated channels was associated with strongly reduced
currents relative to WT channels. The density in mutant-transfected
neurons was similarly reduced by about 80% in both L157V and WT/
L157V channels, and this eﬀect was not signiﬁcantly diﬀerent between
homomeric and heteromeric constructs. In agreement with data in CHO
cells, the activation curves of both L157V and WT/L157V channels
were signiﬁcantly shifted to more positive voltages by about 9mV re-
lative to WT channels (P < .01; Fig. 3C) and time constants of acti-
vation were faster particularly near mid-activation voltages (Fig. 3D).
The quantitatively similar changes of current density and kinetic
properties caused by homomeric and heteromeric mutant channels
again point, as observed in CHO cells, to a dominant eﬀect of the mu-
tation.
In order to verify the net eﬀect on excitability, due to the con-
comitant loss-of-function change caused by a current density reduction
and gain-of-function change due to the rightward shift of the current
activation, we analyzed the contribution of the diﬀerent constructs to
neuronal activity, by ﬁrst measuring the voltage-sag induced by in-
jecting hyperpolarizing current steps (Fig. 4) and then by investigating
neuronal ﬁring and excitability (Figs. 5 and 6).
In Fig. 4A, typical depolarizing sags developing in response to 350
pA hyperpolarizing current injections are shown in neurons transfected
with WT, L157V or WT/L157 channels. Normalized voltage sags in
neurons expressing homozygous or heterozygous mutant channels were
signiﬁcantly smaller (about 30%, Fig. 4B) than those in WT-expressing
neurons. This indicates that the HCN1 contribution to neuronal activity
is reduced by the L157V mutation, and that therefore, in the hy-
perpolarized range of voltages, the current density decrease prevails
over the increased contribution associated with the rightward shift of
the activation curve and acceleration of activation. In accordance with
a decreased contribution of the HCN1 current, neurons transfected with
WT HCN1 had a resting potential signiﬁcantly more depolarized than
either neurons transfected with the L157V construct, both in homo-
meric and heteromeric conditions, or untransfected neurons (WT:
−40.4 ± 2.0mV, n=10; L157V: -51.0 ± 3.5, n=11; WT/L157V:
-53.7 ± 2.6, n=10; untransfected: −51.3 ± 4.8, n=7). These data
therefore suggest that L157V is a loss-of-function mutation.
3.4. Impact of L157V HCN1 mutation on neuronal excitability
In view of the known role of HCN1 channels in shaping neuronal
activity (DiFrancesco & DiFrancesco, 2015; Oyrer et al., 2018), and
having veriﬁed that the L157V mutation aﬀects functional properties of
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the HCN1 channel, we next explored if the expression of mutant
channels modiﬁes the ﬁring properties of neurons.
Sample traces recorded from untransfected neurons and from neu-
rons transfected with WT, L157V and WT/L157V channels during ap-
plication of a depolarizing 40 pA current step of 2 s duration are shown
in Fig. 5A.
Relative to untransfected neurons, expression of WT HCN1 channels
inhibits action potential ﬁring at relatively low values of current in-
jected. Expression of mutant channels, however, regardless of whether
in homomeric or heteromeric conditions, restores the ability of neurons
to ﬁre and re-establishes excitability. Measurement of the cell input
resistance conﬁrmed these results by showing that the input resistance
was signiﬁcantly reduced in neurons expressing WT channels
(480.9 ± 101.4 MΩ n=9) relative to untransfected neurons
(2316.3 ± 483.4 MΩ, n=7) or neurons expressing mutant channels
(L157V: 1560.1 ± 178.0 MΩ, n= 10; WT/L157V: 1993.8 ± 282.6
MΩ, n= 10).
Extending the range of depolarizing current injection steps allows to
investigate the dependence of ﬁring rate upon the stimulus intensity. This
is achieved by plotting, in Fig. 5B, the mean ﬁring rates calculated in the
ﬁrst 500ms of current steps of increasing amplitude (from 10 to 40 pA in
10 pA steps, see Methods) applied to the 4 diﬀerent conditions shown in A.
Fig. 1. A, pedigree of the family investigated. Red indicates the generalized epilepsy phenotype (proband). The crossed symbol represents expression of heterozygous
L157V mutation in HCN1. The mutation is missing in either parents of the proband and is therefore a de novo mutation. B, EEG of the proband showing generalized
sharp waves. C, top, diagram of a single HCN1 subunit showing the approximate position of residue Leu157. C, bottom, 3D ribbon representation of the structure of
hHCN1, based on Cryo-EM reconstruction (Lee and Mackinnon, 2017, PDB ID: 5U6P). Shown are two of the 4 subunits, including core transmembrane domains
(green and orange), HCN domains (blue) and C-termini (red). L157V mutated residues in S1 domains are drawn as space-ﬁlling plots. D, sequence alignment of the S1
and S2 domains of the four hHCN isoforms, indicating the sequence location of the conserved leucine residue in S1 (hHCN1 L157, red background). (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Bonzanni et al. Neurobiology of Disease 118 (2018) 55–63
59
These data clearly indicate that while expression of WT HCN1 chan-
nels strongly depresses neuronal ﬁring (action potentials could only be
elicited by steps>40 pA), transfection with either homomeric or het-
eromeric mutant constructs returns neurons to a highly excitable state.
To further quantify changes in neuronal excitability, we also analyzed
the eﬀect of the mutation on spike threshold. Expression of mutant
channels decreased the spike threshold relative to wild-type channels, as
shown in Fig. 6. In Fig. 6A representative records show that injection of a
150 pA depolarizing current step was required to elicit ﬁring in a neuron
expressing the WT HCN1, while much lower steps (40 pA) were required
to elicit a similar ﬁring pattern in either L157V or WT/L157V-transfected
neurons, and lower still in untransfected neurons.
Fig. 2. Comparison of biophysical properties of homomeric/heteromeric L157V mutant vs wild-type hHCN1 channels expressed in CHO cells. A, representative
current density traces recorded in the range− 45/−125mV (−20mV steps; holding potential− 30mV) in CHO cells expressing WT (n=14), homomeric L157 V
(n=17) and heteromeric WT/L157 V (n=11) mutant channels, as indicated. B-D, graphs showing mean steady-state current density-voltage relations (B), acti-
vation curves (C) and time constants of activation and deactivation (D) for the 3 types of channels (symbols as in A).
Fig. 3. Comparison of biophysical properties of
homomeric/heteromeric L157V mutant vs wild-type
hHCN1 channels expressed in neonatal rat cortical
neurons. A, representative current density traces re-
corded during activation curve protocols. Steps were
applied from a holding potential of− 30mV to the
test range− 35/−115mV in− 20mV steps, and
were followed by a fully-activating step
to− 115mV. B-D, graphs showing mean steady-
state current density-voltage relations (B, WT n=5,
L157V n=7, WT/L157V n=6), activation curves
(C, WT n=7, L157V n=9, WT/L157V n=9) and
time constants of activation (D, WT n=6, L157V
n=7, WT/L157V n=7) for the 3 types of channels
(symbols as in A).
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As shown in Fig. 6B, the mean spike threshold was indeed much
smaller in untransfected, L157V and WT/L157V-expressing neurons
than in WT-expressing neurons.
Taken together, these results clearly indicate that, by reducing the
HCN1 channel contribution to activity, the L157V mutation can induce,
in an in vitro simpliﬁed model of neurons, increased excitability ac-
cording to a dominant eﬀect.
4. Discussion
The genetic causes of generalized epilepsy are not known in a ma-
jority of patients, even in the cases where the transmission of the
phenotype is clearly autosomal dominant. Most likely, there are several
causes contributing to the phenotype, both genetic and environmental.
In the last few years, extensive use of NGS has led to the identiﬁcation
of many genes whose alteration can play a role in epilepsy. A sub-
stantial fraction of these is represented by ion channel genes, whose
dysfunctional mutations can be often shown to be associated with, if not
directly causative of, the disease (Thomas and Berkovic, 2014).
In this work, by analyzing a cohort of patients with genetic epilepsy,
we have identiﬁed for the ﬁrst time a de novo HCN1 mutation in
heterozygosis in an adult patient aﬀected by GGE, without features of
epileptic encephalopathies. Notably, the epileptic phenotype, EEG
characteristics, onset of symptoms and clinical evolution are markedly
diﬀerent from those previously reported in EIEE patients carrying
various de novo HCN1 mutations (Nava et al., 2014a). EIEE patients
were in fact characterized by a severe phenotype, with pharmacore-
sistant epilepsy and unfavorable prognosis in the short term. Moreover,
the L157V mutation is novel and has not been reported in EIEE.
Recent data from cryo-EM resolution of the HCN1 channel structure
(Lee & MacKinnon, 2017) show that the leucine 157 residue is located
in the ﬁrst transmembrane segment S1 of the core domain of the protein
(Lee & MacKinnon, 2017). This location is unlikely to render L157
important as a docking site for regulatory proteins (such as for example
MiRP1 or Trip8b), nor as a site for post-transcriptional modiﬁcation.
Our data show that heterologous expression of the L157V mutation
in CHO cells and in primary neonatal rat cortical neurons reveals a dual
eﬀect: a reduced current density and an increased degree of current
activation due to modiﬁed current kinetic properties.
In details, we found that the expression of the L157V mutation,
regardless whether in homomeric or heteromeric constructs, reduced
signiﬁcantly the amount of the membrane current relative to WT
Fig. 4. Hyperpolarizing voltage sag. A, super-
imposition of representative traces (bottom) re-
corded in response to a 350 pA hyperpolarizing
current step (top) in WT, homomeric L157V and
heteromeric WT/L157V hHCN1-transfected neurons,
as indicated. All recordings were made after setting
the holding resting voltage at− 70mV. All traces
were normalized to the peak of voltage sag, and the
sag was calculated as the a/b ratio (a, b and voltage
bar refer to the WT record). B, bar graph showing
mean voltage sag ratios for the three channel types.
Average values were: WT, 0.17 ± 0.02 (n= 15);
L157V, 0.06 ± 0.01 (n= 7); WT/L157V
0.06 ± 0.03 (n=8)). *p < .05, ANOVA Test.
Fig. 5. Impact of L157V hHCN1 mutation on ﬁring
rate. A, representative traces of AP recordings fol-
lowing the injection of a depolarizing 40 pA current
step in untransfected neurons and in neurons ex-
pressing WT, homomeric L157V and heteromeric
WT/L157V channels, as indicated. All recordings
were made after setting the holding resting voltage
at− 70mV, and the rate was measured during the
ﬁrst 500ms of current injection. B, plot of the mean
ﬁring rates of neurons as a function of injected cur-
rent (untransfected, n= 5; WT, n= 10; L157V,
n= 11; WT/L157V, n=10; symbols as in A). Lines
drawn through points.
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channels, according to a loss-of-function eﬀect. At the same time,
changes in kinetic properties of channels led to gain-of-function eﬀects,
characterized by a shift of the current activation curve to more positive
voltages, a faster activation and a slower deactivation (this latter only
observed for technical reasons in CHO cells). These modiﬁcations were
again similar in homomeric and heteromeric constructs, ruling strongly
in favor of a dominant eﬀect of the mutation. The above eﬀects were
more pronounced in neurons than in CHO cells, possibly implying a
more eﬀective “context” dependence in homologous than in hetero-
logous expression systems.
In order to verify if and how these changes impact neuronal excit-
ability, we then turned to analyze potential modiﬁcations of electrical
activity of neurons caused by expression of mutant channels.
We ﬁrst analyzed the voltage sag response in neurons and found
that, in neurons expressing either homomeric or heteromeric L157V
mutant channels, a reduced depolarizing “sag” was elicited in response
to hyperpolarizing steps, indicating a loss-of-function eﬀect relative to
WT channels.
Also in accordance with a loss-of-function eﬀect of the mutation, we
found that the ﬁring rate in response to depolarizing voltage steps was
strongly ampliﬁed in neurons expressing mutant rather than WT HCN1
channels, an eﬀect recorded irrespectively of whether expressed chan-
nels were homomeric L157V or heteromeric WT/L157V. Spike
threshold was also correspondingly decreased in neurons expressing
mutant channels.
The increased excitability of mutant-expressing neurons was quan-
titatively similar to that of untransfected neurons, in agreement with
the notion that these neurons normally express a small Ih current
(DiFrancesco et al., 2011).
These results can be summarized to indicate that neurons expressing
mutant channels are more excitable than WT-expressing neurons, due
to a reduced amount of IHCN1 current. They represent the ﬁrst evidence
in a neuronal model that missense variants of HCN1, causing a loss-of-
function eﬀect, determine an increase of neuronal excitability and
discharge activity, potentially associated with epileptogenesis.
This is in line with previous observations that missense point mu-
tations of HCN1 are poorly tolerated and associated with epilepsy,
while non-sense variants do not alter neuronal discharge activity (Nava
et al., 2014b).
Although the cellular eﬀects we have observed are clear-cut in in-
dicating an L157V-linked increase of neuronal excitability, the ob-
servation of the transmission of the disease within the family suggests a
complex etiological pattern, where the mutation appears to be a
contributing rather than a causative factor. Indeed the L157V HCN1
mutation only partially segregates with the disease, since it has been
identiﬁed as a de novo mutation only in the proband, whose epileptic
phenotype is more severe than that of the sisters (typical absence epi-
lepsy) and the mother (single febrile seizure in infancy, without epi-
lepsy) who do not carry the mutation. All the siblings were analyzed
with an extensive NGS investigation in order to identify any adjunctive
cause potentially responsible for the disease, however with negative
results. We can thus hypothesize that the L157V HCN1 mutation im-
portantly contributes to the phenotype of the proband, but that also
other undetermined causes are likely to have a role in the disease in this
family.
This study reports for the ﬁrst time a de novo heterozygous missense
mutation of HCN1 in a patient with GGE, characterized by a dominant
negative loss-of-function eﬀect on channel contribution to activity. As
for other channelopathies with variable characteristics and severity (i.e.
SCN1A (Gambardella and Marini, 2009) and KCNQ2 (Miceli et al.,
2013)), HCN channelopathies are emerging as potential key players in
human epilepsy. Even though we cannot completely rule out the pre-
sence of other causative factors, the lack of any other mutation in al-
most eighty epilepsy-associated genes (Table 1) strengthens the hy-
pothesis that the L157V HCN1 mutation may participate in the onset of
the disease as an important predisposing factor. Our data also suggest
that it may be important to perform HCN screening in subjects aﬀected
by GGE, which may help to increase the understanding of the patho-
genic mechanisms leading to the development of the disease. This
knowledge will be useful to identify innovative therapeutic strategies
through the selective modulation of HCN channels, for the improve-
ment of the treatment of patients.
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